Mallinckrodt Nuclear Medicine LLC

Mallinckrodt Nuclear Medicine LLC is a focused provider of advanced nuclear medicine solutions, delivering essential products for diagnosis and treatment in patient care. Founded in 2014, Mallinckrodt Nuclear Medicine LLC operates from St. Louis, US, offering specialized nuclear medicine products. It is part of Mallinckrodt Pharmaceuticals and has undergone significant operational focus on specialty pharmaceuticals.

The company has made one known deal, with the most recent deal closing in August 2016, which involved the acquisition of its Nuclear Imaging Business by IBA Molecular for USD 690 mn. Mallinckrodt Pharmaceuticals specializes in developing and delivering a range of specialty pharmaceutical products that address significant medical needs, primarily focusing on pain management, immunotherapy, and rare disease treatment. Their core offerings include branded medications such as H. P.

Acthar Gel, utilized for several indications, including acute exacerbations of multiple sclerosis and infantile spasms, and the opioid analgesic, Xartemis XR, which aids in pain management. The products enhance patients' quality of life through effective solutions for complex health conditions. Their customer base includes healthcare professionals, hospitals, and pharmacy networks, with end-users being patients suffering from chronic pain, severe autoimmune disorders, or rare diseases, marketed across North America, Europe, and parts of Asia. Mallinckrodt Pharmaceuticals generates revenue through pharmaceutical product sales to healthcare providers and institutions, primarily driven by direct sales to hospitals, specialty pharmacies, and outpatient clinics.

Products like H. P. Acthar Gel and Xartemis XR are critical components in treatment regimens, supported by established contracts that specify pricing and supply terms, emphasizing direct engagement with healthcare providers for timely access to specialty medications. Mallinckrodt Nuclear Medicine LLC aims to expand its product line with upcoming releases and enhance its market presence.

The funding raised from the recent Add-on round, led by Curium with USD 690 mn, will support these initiatives. The acquisition of the Nuclear Imaging Business by IBA Molecular is set to complete by January 2017, showcasing strategic pivots to optimize operations and explore additional market opportunities.